Next-Generation Bispecific Nanobody Targeting ALB and Complement C5 for Complement-Mediated Diseases

VHH-P733 is an innovative, humanized bispecific nanobody designed to simultaneously target albumin (ALB) and complement C5 (C5). This fusion construct is currently in the biological testing stage and is developed for potential treatment of complement-mediated diseases. ALB plays a key role in maintaining plasma oncotic pressure and transporting various molecules, while C5 is a central effector in the complement cascade, driving inflammation and tissue damage in complement-related pathologies. Harnessing its dual specificity, VHH-P733 provides a promising approach to modulating complex disease processes associated with aberrant complement activation and offers novel therapeutic potential for patients.

Licensing Opportunity

VHH-P733 is available for licensing and collaborative development. We welcome partnerships with biopharmaceutical companies and research institutions to advance this promising bispecific nanobody program to the next stage.

Development Phase

Modality

VHH-P733 utilizes a humanized bispecific nanobody architecture, comprising a single-domain antibody targeting ALB linked via a flexible G4Sx3 linker to a VHH domain directed against complement C5. Expressed in HEK293F cells, this design results in a small, stable molecule with advantageous tissue penetration compared to conventional antibodies. The nanobody format enables robust expression, high solubility, and increased stability under physiological conditions. These biophysical characteristics are particularly advantageous for targeting complement-mediated diseases, where distributed tissue involvement and rapid pharmacokinetics demand optimized delivery and bioavailability. The modularity of the design further facilitates potential therapeutic adaptations.

Target

ALB and complement C5 are critical molecular targets in the context of complement-mediated disease. ALB, a major plasma protein, is essential for maintaining osmotic pressure and acts as a key transporter for drugs, hormones, and metabolites. It is abundantly expressed in the liver and circulates systemically. Complement C5, a central protein of the complement system, is produced primarily in the liver and circulates in plasma, mediating terminal complement pathway activation. Dysregulated activity of C5 drives pathogenesis in multiple complement-mediated diseases. Strategic targeting of ALB and complement C5 enables VHH-P733 to enhance half-life and systemic distribution via ALB-binding, while modulating complement overactivity through C5 inhibition. This dual approach leverages the pharmacokinetic benefits of ALB engagement and the therapeutic benefits of C5 blockade, offering strategic advantages for broad application in complement-driven pathologies.

Mechanism of Action

VHH-P733 functions by dually engaging ALB and complement C5 through two distinct single-domain antibody interfaces. The anti-ALB moiety enables reversible binding to ALB, potentially extending systemic exposure, while the anti-C5 component inhibits complement activation by directly targeting C5, thereby reducing downstream inflammation and tissue injury. This bispecific configuration leverages the advantages of nanobody technology, such as small molecular weight and high tissue permeability. The platform's modularity supports additional formats, such as antibody-drug conjugates or multivalent constructs, broadening therapeutic scope for other immune-mediated indications. By simultaneously manipulating target pharmacokinetics and pathogenic complement activity, VHH-P733 represents a new class of targeted therapies.

Complement-mediated Disease

Complement-mediated diseases represent a diverse group of disorders characterized by aberrant activation or dysregulation of the complement system, a crucial component of innate immunity. These conditions include rare but serious diseases such as atypical hemolytic uremic syndrome, paroxysmal nocturnal hemoglobinuria, and certain glomerulopathies. The clinical presentations are diverse, often involving tissue inflammation, cellular lysis, and organ dysfunction. Current treatment strategies may include immunosuppressants or complement inhibitors, which are frequently associated with high cost, infection risk, and incomplete disease control. There remains a substantial unmet need for safer, more targeted therapies capable of modulating specific complement components while enhancing patient convenience and outcomes. VHH-P733, with its dual targeting approach and nanobody-based attributes, holds significant therapeutic potential to address current limitations and deliver new standards of care in this challenging disease area.